Updated: Agilent throws down $725M to double manufacturing capacity for nucleic acids to meet API demand
A life science CDMO is investing hundreds of millions of dollars into manufacturing nucleic acids amid increasing demand for active pharmaceutical ingredients, or API.
Agilent Technologies, which spun out of American tech giant Hewlett Packard back in 1999, put the word out on Monday, saying that the $725 million will be used to double the company’s current manufacturing capacity for therapeutic nucleic acids. These nucleic acids, also known as therapeutic oligonucleotides, are DNA or RNA molecules that act as the API for certain drugs that target indications such as cancer or rare diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.